Peptides in Dental Practice
A clinician-to-clinician primer on where peptide adjuncts have a defensible role in dentistry, what the evidence actually says, and how to evaluate fit for a specific case. Sales reference and webinar source materials in one volume.
Executive summary
The thesis, the honest framing, and how to use this package.
Peptides have a real and increasingly defensible clinical role in dentistry. The evidence today is preclinical-leaning, with a growing body of human work concentrated in periodontal regeneration, soft-tissue healing, and post-surgical recovery. This package is honest about where that evidence is strong, where it is suggestive, and where it is still hypothesis.
The thesis
The peptide industry has largely ignored dentistry. Most commercial peptide marketing has been built around performance, recovery, and aesthetics, and the messaging in those categories has consistently outrun the data. Dentistry is the opposite problem. The biology that underpins the dental case for peptides, particularly BPC-157 in periodontal and soft-tissue contexts and GHK-Cu in wound healing, is among the most rigorously studied applications in the entire peptide literature. The disconnect between the quality of the dental science and the silence of the dental market is the opening Opal is stepping into.
Opal Peptides is a clinician-supplied, research-grade pathway for indicated cases. We are not a consumer brand, we are not a wellness brand, and this package is not a prescription guide. It is a clinician-to-clinician primer assembled by a working dental advisor, a research lead, and a clinical pharmacologist, intended to be read before any case decision is made.
What this package is
- A clinical reference, organized by procedure rather than by molecule.
- An evidence map that grades each indication honestly (preclinical, mechanistic, early human, established).
- A protocol reference framed around adjunctive use in research-grade clinician-directed settings.
- A starting point for a discovery conversation with an Opal clinical advisor.
What this package is not
- A prescription guide.
- A standard-of-care recommendation.
- A claim that peptides replace existing surgical or pharmacologic protocols.
- A consumer-facing document.
How to use it
Read the executive summary and the evidence section (F-J) first. If a clinical scenario in Section B maps to a current patient case, the protocol reference in Section I will give you the framework to evaluate fit. Share with case-appropriate colleagues. When a case looks like a candidate for an adjunctive peptide protocol, book a discovery call with an Opal advisor before any patient conversation.
Why dental, the unworked niche
A strategic clinical case for why peptides have a real but under-marketed role in dental practice.
Peptides have been sold into medical aesthetics, regenerative medicine, longevity, and sports recovery for the better part of a decade. Dentistry, despite being the medical specialty whose entire daily workload is wound healing in a contaminated field, has been left almost entirely out of the conversation. That is a marketing failure, not a clinical one. The biology that peptide brands have leaned on in aesthetics and orthopedics, angiogenesis, fibroblast activity, modulation of inflammatory cytokines, accelerated soft-tissue and bone healing, is the same biology a periodontist, an oral surgeon, or an implant clinician is trying to coax out of every flap, every socket, and every graft. The story for dentistry is not weaker than the story for aesthetics. It is more rigorous, because the procedures are more standardized and the outcomes are measurable.
What has held dentistry back is partly the wellness-industrial framing. When peptides are pitched as "regeneration" or "anti-aging" without procedural anchoring, the dental clinician hears it as supplement marketing and tunes out. Periodontists in particular live next to the gold-standard regenerative literature (Emdogain, rhPDGF, rhBMP-2) and will not accept a peptide pitch that ignores those comparators or pretends the evidence base is equivalent. The honest position is the one Opal is built on: peptides are biologically plausible adjuncts in specific procedural contexts, supported predominantly by animal models and mechanistic extrapolation, sometimes by small human pilot work, with no FDA clearance for any dental indication as of 2026. That framing, stated clearly, is more defensible to a dental audience than any version of the wellness pitch.
The under-marketing creates a real opening. Compounded peptide Rx through a 503A pharmacy is already a legitimate pathway for dentists in broad-scope states (Texas, Florida, Arizona, Nevada, much of the Mountain West) and a more cautious but practiced one elsewhere. The procedures where the peptide story holds up clinically (post-extraction healing in compromised patients, implant osseointegration support, periodontal regenerative surgery, mucogingival grafts, peri-implantitis adjuncts, oral mucositis in oncology) are exactly the procedures that drive the highest-margin chair time in a modern cash-pay-skewed dental practice. The dental sub-audiences best positioned to adopt (OMS, periodontists, implant specialists, holistic and biological GPs, cash-pay cosmetic GPs) have the prescribing scope, the patient economics, and the case mix to make this work. No major peptide brand has spoken to them coherently. That is the niche.
What this package will not do is overstate. Opal will not claim that peptides regenerate teeth, replace FDA-cleared regenerative agents, or cure peri-implantitis as standalone therapy. The reason that matters strategically is that periodontists, the most credentialed sub-audience in dentistry, will validate or dismiss the brand on the first reading of the evidence section. Get that right, and the rest of the dental profession follows. The dentistry vertical for Opal is built on calibrated honesty as a differentiator, not as an apology.
By procedure, where peptides actually fit
Six procedure-by-procedure cards covering the clinical problem, current standard of care, peptide adjunct case with evidence tier, candidate patient, and honest limits.
B1 · Post-extraction socket healing in compromised patients
B2 · Post-implant osseointegration support
B3 · Periodontal regenerative procedures
B4 · Mucogingival surgery
B5 · Peri-implantitis adjunctive management
B6 · Oral mucositis in head and neck oncology
By audience, which sub-specialty maps to which use case
The dentistry vertical is not one audience. The same peptide claim will land differently with a periodontist, an OMS, a cash-pay cosmetic GP, and a holistic dentist.
General dentists (GPs)
The largest single audience at every major dental show, but the most heterogeneous in adoption likelihood. The cash-pay filter matters more than the GP label. The cash-pay-skewed cosmetic and implant-restoring GP is a faster adopter than the insurance-driven volume-restorative GP.
Top use cases: Post-extraction socket healing in compromised patients (B1, the universal entry point); post-implant osseointegration support (B2) for the GP who places or restores implants; mucogingival surgery recovery (B4) for the cosmetic-leaning GP. Skip: periodontal regenerative surgery, peri-implantitis surgical management, oral mucositis (all referred).
Periodontists
The most credentialed audience and the one whose validation matters most for credibility across the entire profession. They live in regenerative biology and will validate or dismiss the brand on the evidence section first.
Top use cases: Periodontal regenerative procedures (B3, adjunct to EMD or rhPDGF, never substitute); mucogingival surgery (B4, GHK-Cu topical adjunct); peri-implantitis adjunctive management (B5, anti-inflammatory and healing support post-surgical). Periodontists will respond to honest evidence framing more than any other dental audience. Overreach is the fastest way to lose them.
Oral and maxillofacial surgeons (OMS)
The highest-LTV dental sub-audience for peptide brands. Full Rx scope nationally, surgical case mix dominated by recovery-intensive procedures, accustomed to evidence-based adjunct decisions.
Top use cases: Post-extraction socket healing in MRONJ-risk and complex medical patients (B1); post-implant osseointegration in immediate-load, full-arch, and grafted cases (B2); regenerative procedures and mucogingival surgery (B3 and B4) where part of case mix. Will also engage with B5 and B6 in subspecialty practices.
Implant specialists
Often dual-trained as OMS or periodontists. The cash-pay implant economy is one of the fastest-growing segments in dentistry and one of the best peptide-adjacent target audiences.
Top use cases: Post-implant osseointegration support (B2, especially compromised bone and full-arch); peri-implantitis adjunctive management (B5); mucogingival surgery (B4) for peri-implant soft tissue.
Holistic and biological dentists
A self-selected audience (IAOMT, IABDM certified) that is cash-pay by definition, adjunct-receptive, and oral-systemic-framed. Peptide adoption is faster here than in any other sub-segment, but the framing must respect the clinical baseline. Many holistic and biological dentists are board-certified specialists who maintain mainstream practice. Do not write to them as if they were the supplement-industry fringe.
Framing differences: Lead with oral-systemic positioning. Emphasize biocompatibility and the absence of synthetic-pharma overreach. RUO research-grade peptides through a 503A pathway is consistent with this audience's framework. Use cases that resonate: B1 (compromised healer adjuncts), B4 (esthetic soft-tissue work), B6 (mucositis in oncology dental patients seen in integrative practices).
Where Opal does not target in the dentistry vertical
Orthodontists: weak peptide fit. Tooth movement biology is mechanically-induced bone remodeling, not surgical recovery. Dental sleep medicine practitioners: no peptide fit. Different physiology entirely. Pediatric dentists: limited peptide indications and informed consent complexity. DSO-employed dentists: low priority in early rollout due to corporate formulary control. Endodontists: regenerative endodontics is research-active but commercial peptide story not yet developed. Re-evaluate in 12 to 24 months.
What this is not, the honest limits
The credibility section. Periodontists, OMS, and any clinically literate dental audience will read the rest of the package looking for overreach. If they find it, the brand loses credibility for everything else.
Opal does not claim that peptides regenerate teeth
No peptide on the catalog, alone or in combination, regrows enamel, dentin, pulp, or a tooth that has been lost. The regenerative biology that peptides participate in operates at the soft tissue, bone, and ligament level. Dental tissue regeneration in the sense of growing back a lost tooth is research territory (stem cell scaffolds, induced pluripotent approaches, regenerative endodontics for immature permanent teeth) that does not currently involve commercial peptides.
Opal does not claim that BPC-157 cures peri-implantitis as standalone therapy
Peri-implantitis is a multifactorial inflammatory and biofilm-driven disease around a non-shedding metal surface. The mechanical decontamination of the implant surface, surgical access where indicated, and management of the underlying contributors (occlusal load, plaque control, smoking, glycemic control) are not optional. BPC-157 is biologically plausible as an anti-inflammatory and healing adjunct during the post-surgical phase. It is not a substitute for the procedural standard of care.
Opal does not claim that compounded peptide is equivalent to FDA-cleared regenerative agents
Enamel Matrix Derivative (Emdogain), recombinant human PDGF-BB (GEM 21S), and recombinant human BMP-2 (Infuse) are FDA-cleared regenerative agents with pivotal RCT evidence in specific dental indications[26][29][32]. Compounded BPC-157, TB-500, GHK-Cu, and KPV are research-grade peptides obtained through a 503A compounding pharmacy pathway with no FDA clearance for any dental indication. These are clinically and legally distinct categories. The defensible position is "adjunct to, not replacement for" the FDA-cleared agents.
Opal does not claim that peptides replace standard wound healing technique
Atraumatic extraction, primary stability at implant placement, tension-free flap closure, appropriate graft material selection, proper soft-tissue handling, and operator surgical skill are not made obsolete by adjunct biologics. The peptide story is marginal value-add on top of correct technique, most plausibly in compromised cases where the standard of care alone produces less predictable outcomes.
Opal does not claim regulatory clearance for any dental indication
As of 2026-05, no peptide on the Opal catalog has FDA clearance for any dental use. Compounded peptide Rx by a dentist operates through state-defined dental practice scope and a 503A compounding pharmacy relationship, which is a legitimate but distinct regulatory pathway from FDA clearance. The FDA Pharmacy Compounding Advisory Committee was scheduled to revisit BPC-157, KPV, TB-500, and MOTs-C on the 503A bulks list in July 2026[10]. Note: WADA prohibits BPC-157 for competitive athletes[11] — flag for athlete-patient overlap.
Opal does not import aesthetic or skincare claims into dental contexts
The dermatology evidence for GHK-Cu in skin wound healing is real and extensive, but oral mucosa heals faster than skin at baseline. Importing dermatology copy wholesale into dental contexts misrepresents the differential evidence base. The dental claim for GHK-Cu is mucosal healing quality in the surgical context, not anti-aging or general regeneration.
What Opal IS claiming
Opal supplies research-grade compounded peptides through a clinician channel for use under a dentist's clinical judgment in indications where the biologic mechanism is plausible, animal or mechanistic evidence supports the use, and the patient is appropriate. The clinician is the prescriber. The peptide is the adjunct. The standard of care is the foundation. The evidence base is what it is, and Opal will represent that honestly to the practitioner audience and through the practitioner to the patient.
FAQ for dental practice owners
Twelve questions a working dentist or dental practice owner would actually ask, with honest answers calibrated to the working-dentist tone.
- 1. Is this legal for me to prescribe in my state?
It depends on state-defined scope of dental practice. Broad-scope states (Texas, Florida, Arizona, Nevada, much of the Mountain West) generally accept compounded peptide Rx by a dentist for indicated dental cases when prescribed through an established 503A compounding pharmacy and within clinical judgment. Restrictive states (California, New York, Massachusetts, New Jersey) interpret "practice of dentistry" more narrowly and the regulatory environment is more cautious; some dentists do practice this way in those states with appropriate documentation, but regulatory risk is non-zero. OMS have the broadest scope nationally due to their dual surgical and medical training. Opal will support you in identifying state-specific scope guidance, but the prescribing decision and documentation are yours.
- 2. What is a 503A compounding pharmacy and why does it matter?
503A pharmacies are state-licensed compounding pharmacies that prepare patient-specific compounded medications based on an individual prescription, under USP <797> sterile compounding standards. This is the legitimate regulatory pathway for clinician-prescribed compounded peptides. It is distinct from 503B outsourcing facilities and from research-only product supply. Opal supplies research-grade peptide product; the dispensing for patient use happens through a 503A partner that you, the prescribing dentist, are working with. Several 503A pharmacies have dentistry-specific protocol support; we can recommend partners by region.
- 3. What about liability and informed consent?
Standard informed consent practice applies. The patient should understand: (a) the peptide is being used as an adjunct, not as a replacement for standard of care; (b) the peptide is compounded research-grade product, not FDA-cleared for the dental indication; (c) the evidence base is preclinical and mechanistic with limited human dental data; (d) the rationale for the recommendation in their specific case. Carrying professional liability insurance that covers compounded medication use is recommended; most major dental liability carriers cover this with appropriate disclosure. Document the informed consent conversation and the patient's specific indications.
- 4. How much chair time does this add to a procedure?
For systemic injectable peptide protocols (BPC-157, TB-500), the actual chair-time impact is minimal: the patient self-administers at home, or in some practices the patient receives an initial dose chairside (5 to 10 minutes including consent). For topical applications (GHK-Cu, KPV in oral rinse formulations), the chair-time impact is essentially zero at the procedural visit, with patient instruction adding 5 minutes. The chair-time impact at the introduction visit (case presentation, informed consent, protocol explanation) is typically 15 to 20 minutes; many practices fold this into the consultation visit before the procedure.
- 5. How do I introduce peptide adjuncts to a hesitant patient?
Lead with the clinical problem in their case, not the mechanism. "You have controlled diabetes and you are a former smoker. The extraction site we are about to graft is going to heal more slowly than in a healthier patient, and the predictability of the bone fill matters for the implant we are planning. There is an adjunct healing protocol that some of our patients in your situation use; the evidence is preclinical and mechanistic, not yet from large human trials, but the biology is well-understood and we are happy to discuss whether it is right for you." Patients in compromised-healer situations are often actively looking for ways to improve their outcomes and respond well to honest framing. Patients without a clear clinical indication are generally not appropriate candidates.
- 6. What does it cost the practice and what can I bill the patient?
Wholesale peptide cost for a typical protocol (4 to 8 week course of BPC-157, with or without GHK-Cu or TB-500) ranges from $80 to $300 depending on peptides selected, doses, and pharmacy. Practice markups in cash-pay adjunct categories typically range from 2x to 4x wholesale, putting patient-facing pricing in the $200 to $1,200 range. Most practices structure this as a cash-pay adjunct service line, not as a billable dental code. Pricing should reflect the practice's overall cash-pay positioning and the procedural margin available.
- 7. Where should I start, in terms of case selection?
The recommended first cases are post-extraction socket healing in compromised patients (B1). Reasons: every dental practice encounters these patients, the clinical indication is unambiguous (diabetic, smoker, bisphosphonate, immunocompromised), the protocol is simple (typically 4 to 6 week course of systemic BPC-157 with optional topical GHK-Cu), the outcome is observable (epithelialization, soft tissue closure, bone fill on radiographs), and the patient population is most receptive to adjunct healing support. Once the practice is comfortable with the protocol logistics, expand to implant osseointegration cases (B2). Save peri-implantitis (B5), regenerative perio (B3), and mucositis (B6) for after the practice has direct experience with simpler protocols.
- 8. What kind of training do I need before I start?
A 60 to 90 minute clinician education session covering: the peptide catalog and the dental-specific evidence base, protocol options by procedure category, case selection criteria, informed consent language, 503A pharmacy ordering workflow, and documentation and follow-up. Opal hosts these sessions for practitioner advisors and we run them by webinar and in-person. Self-paced clinician materials including this clinical content package are available for asynchronous review. We do not recommend introducing peptide protocols to your practice without dedicated clinician education first.
- 9. How does this fit with my existing referral relationships?
For the GP, peptide adjunct use in your own cases (compromised extractions, simple implant restorations, post-op care) does not affect your specialist referral pattern. For periodontal regenerative surgery, peri-implantitis, and complex implant cases that you refer out, the specialist may or may not use peptide adjuncts in their own protocols. The conversation with your specialist partners about peptide protocols is worth having; many specialists are already using or considering these adjuncts and a coordinated approach across the referral relationship benefits the patient.
- 10. What is the evidence base, in honest terms?
Across the peptides used in dental contexts, the evidence base is predominantly animal models and mechanistic extrapolation, with small case series and pilot work in human dental populations. The strongest dental-specific animal evidence is TB-500 (two independent rat models[15][16]) and BPC-157 (one rat ligature-induced periodontitis study[1]). No peptide has FDA clearance for any dental indication. Compared to FDA-cleared regenerative agents (Emdogain, rhPDGF, rhBMP-2), peptides sit one or two evidence tiers lower. The defensible clinical use is as adjuncts in cases where the biologic mechanism aligns with the clinical need and where the evidence-tier limitation is part of the informed consent conversation.
- 11. What about peptide quality and safety on the supply side?
Opal supplies research-grade peptides with third-party-tested purity, identity, and sterility for sterile injectable preparations. Lot-specific certificates of analysis are available. The 503A compounding pharmacy that prepares the patient-specific prescription is responsible for the final sterile compounding step under USP <797>. Adverse event reporting and patient safety processes follow standard compounded medication protocols. Detailed quality documentation is available to clinician partners.
- 12. What is the long-term picture, where is this category going?
The evidence base in peptide-in-dentistry is developing. Human RCTs in periodontal regeneration and post-extraction healing populations are anticipated over the next 3 to 5 years; some are already enrolling outside the US. The regulatory environment for compounded peptides has tightened over the past several years and may continue to do so; certain peptides have moved between categories on the FDA bulk substances list. Opal monitors regulatory developments and adjusts the catalog accordingly. Practices that adopt early and build clinical experience with peptide adjuncts are positioned to expand use as the evidence base matures.
What the evidence actually says
Tier-graded evidence summary for each peptide in the Opal dental story. Honest assessment; gaps surfaced as readily as positive evidence.
Tier framework
- Tier 1 FDA-approved indication
- Tier 2 Multiple human RCTs in dental populations
- Tier 3 Pilot human studies / case series / single small RCT in dental populations
- Tier 4 Robust animal model with dental-relevant outcomes
- Tier 5 Mechanistic plausibility from non-dental evidence
BPC-157 (pentadecapeptide body protection compound)
Evidence tier (highest, dental): Tier 4
Strongest dental indication evidence: One published proof-of-concept rat study (Keremi et al., 2009) showing systemic BPC-157 reduces gingival inflammation and alveolar bone resorption in a ligature-induced periodontitis model[1].
Mechanism (verified): Promotes angiogenesis via VEGFR2 upregulation and the Akt-eNOS pathway; modulates nitric oxide production; accelerates the collagen / inflammatory cell / angiogenesis healing triad; upregulates growth-factor receptor expression rather than ligand production[2][3].
Dental-specific human evidence: None published. No PubMed-indexed human trial of BPC-157 for any periodontal, peri-implant, mucosal, or oral surgical indication exists as of preparation.
Adjacent evidence: Achilles tendon-to-bone healing[4]; broad wound-healing review[5]; peripheral nerve regeneration[6]; GI ulcer cytoprotection[7]. Human safety pilots: a 2021 retrospective intra-articular knee-pain chart review (n=16)[8]; a 2025 IV pilot (n=2)[9]. These are not adequate human safety datasets.
Honest framing for clinician copy: BPC-157 has a single, well-designed rodent periodontitis study showing reduced inflammation and alveolar bone loss, plus a broad preclinical wound-healing signal across multiple tissues. No human dental trial has been published. Regulatory status in the United States is unsettled: the FDA placed BPC-157 on the Category 2 bulk-substances list under its Interim Policy on compounding in 2023, and the Pharmacy Compounding Advisory Committee was scheduled to revisit BPC-157 and related peptides on the 503A bulks list in July 2026[10]. WADA prohibits BPC-157 for competitive athletes[11].
GHK-Cu (glycyl-L-histidyl-L-lysine-copper)
Evidence tier (highest, dental): Tier 5
Strongest dental indication evidence: No PubMed-indexed dental-specific human or animal study of GHK-Cu was identified. Evidence is mechanistic and skin/wound-derived.
Mechanism (verified): Stimulates collagen and glycosaminoglycan synthesis in dermal fibroblasts at nanomolar concentrations[12]; modulates matrix metalloproteinases; recruits immune and endothelial cells to injury sites; increases VEGF and bFGF expression; gene-expression profiling implicates GHK in modulation of thousands of human genes related to repair and antioxidant defense[13][14]. Copper is a cofactor for lysyl oxidase, the cross-linking enzyme for collagen and elastin.
Dental-specific evidence: None published. Reviewer should flag any clinician copy claiming "studies show GHK-Cu regenerates gingiva" as unsupported.
Adjacent evidence: Stimulates wound contraction and skin-graft take in animal wound models; clinical cosmetic studies show improved skin appearance, density, and reduced wrinkling with topical formulations; well-characterized fibroblast biology. The Pickart group has 50+ years of mechanistic publications on GHK-Cu in non-dental tissues.
Honest framing: GHK-Cu is a Tier 5 candidate for dental applications. The mechanistic case is strong, copper biology is genuinely relevant to oral wound healing, and dermal evidence is robust. Dental-specific evidence does not exist. Clinicians may reasonably explore GHK-Cu as an adjunct based on mechanistic plausibility and skin precedent, but should not represent it as having dental clinical evidence.
TB-500 (thymosin beta-4, Tβ4)
Evidence tier (highest, dental): Tier 4
Strongest dental indication evidence: Two animal studies with dental-relevant outcomes: (1) Matsuo et al., 2012 — Tβ4 accelerated granulation tissue and new bone formation in rat post-extraction sockets[15]; (2) Zhu et al., 2014 — Tβ4 accelerated re-epithelialization of palatal mucosal wounds in rats[16]. One in-vitro study (Lee et al., 2016) showing Tβ4 suppresses osteoclastogenesis and inflammation in human periodontal ligament cells[17]. TB-500 has the strongest dental-relevant preclinical signal of the four peptides in the Opal portfolio.
Mechanism: Actin-sequestering peptide present in all human cells except erythrocytes; promotes cell migration without affecting proliferation; suppresses NF-κB signaling; reduces inflammatory cytokines; promotes angiogenesis; anti-apoptotic; suppresses osteoclastic differentiation via MAPK and NF-κB pathways in periodontal ligament cells[17][18][19].
Dental-specific human evidence: None published in PubMed for any dental indication. The phase II/III ophthalmic program (RGN-259) provides the closest human safety and efficacy precedent on a mucosal surface, with mixed results: phase II dry-eye improvement[20]; phase III neurotrophic keratopathy trial narrowly missed primary endpoint (p=0.0656)[21]. Not dental data, but establishes ophthalmic-surface tolerability.
Honest framing: TB-500 has the strongest dental-relevant animal evidence of any peptide in the Opal portfolio, with two independent rat studies showing benefit at extraction sockets and palatal wounds plus an in-vitro PDL cell study. No human dental trial exists. The closest human evidence (ophthalmic) is on a mucosal surface and is mixed.
KPV (Lys-Pro-Val, α-MSH C-terminal tripeptide)
Evidence tier (highest, dental): Tier 4
Strongest dental indication evidence: One animal-and-cell study (Yang et al., 2022) showing a KPV-loaded mucoadhesive hydrogel reduced inflammation, accelerated re-epithelialization, and reduced bacterial colonization in chemotherapy-induced oral mucositis in rats[23]. Single laboratory; not independently replicated.
Mechanism: C-terminal tripeptide of α-MSH; anti-inflammatory effect is PepT1-mediated rather than melanocortin-receptor-mediated[24]; inhibits NF-κB and MAPK signaling; downregulates TNF-α, IL-1β, IL-6; upregulates IL-10; small enough for oral bioavailability.
Adjacent evidence: Robust murine IBD evidence; oral KPV reduces DSS and TNBS colitis severity[25]. The PepT1 transporter is expressed in inflamed epithelium broadly, which extends the mechanistic relevance to oral mucosa.
Honest framing: KPV has a single rat oral-mucositis study and strong mechanistic support from IBD literature. No human dental data. Like BPC-157, KPV is included on the FDA Pharmacy Compounding Advisory Committee 2026 agenda for 503A bulks list consideration[10].
Comparison: peptide adjuncts vs FDA-approved regenerative agents
The Opal peptides set alongside the three FDA-approved regenerative biologics currently used in periodontal and oral-maxillofacial practice. Tiers refer to the dental indication specifically.
| Agent | Mechanism | FDA dental indication | Tier | Best clinical use | Cost / case | Opal framing |
|---|---|---|---|---|---|---|
| Emdogain (EMD) | Amelogenins induce acellular cementum-like matrix; mesenchymal cell recruitment | Periodontal regeneration in intrabony defects | T1/T2 | Intrabony defects with adequate vascular wall support; recession coverage adjunct[26][27] | $200–$400 per syringe | Opal peptides are not regenerative substitutes for EMD. Frame as adjuncts for soft-tissue healing, post-op inflammation, mucosal recovery. |
| rhPDGF-BB (GEM 21S) | Recombinant platelet-derived growth factor in β-TCP carrier | Periodontal osseous defects and furcations (FDA-approved 2005) | T1/T2 | Two- and three-wall intrabony defects; root coverage; ridge preservation[29][30] | $400–$800 per kit | Opal peptides do not compete with GEM 21S for hard-tissue regeneration. Position as adjunctive comfort and mucosal healing. |
| rhBMP-2 (Infuse) | Recombinant bone morphogenetic protein-2 on collagen sponge; osteoinductive via SMAD | Maxillary sinus floor augmentation and localized alveolar ridge augmentation (FDA-approved 2007) | T1/T2 | Sinus floor augmentation when autograft morbidity is to be avoided[31][32] | $1,500–$3,500 per case | Opal peptides do not replace rhBMP-2 for sinus or ridge augmentation. Soft-tissue and post-op healing roles only. |
| BPC-157 | Pro-angiogenic via VEGFR2 and Akt-eNOS; modulates NO; broad wound healing | None | T4 | Investigational adjunct for soft-tissue inflammation and post-operative healing[1] | Compounded; variable. Regulatory status pending PCAC[10] | "Mechanistically plausible adjunct under active research; no human dental trial; describe alongside FDA-approved biologics, not as a substitute." |
| GHK-Cu | Copper-binding tripeptide; collagen and GAG synthesis; MMP modulation; angiogenic; antioxidant | None | T5 | Investigational adjunct for soft-tissue tone and post-op mucosal recovery; cosmetic precedent only[12][14] | Compounded; cosmetic $50–$200 | "Strong mechanistic basis from skin biology; no dental clinical evidence; do not claim dental regeneration." |
| TB-500 (Tβ4) | Actin-sequestering peptide; cell migration, angiogenesis, anti-inflammatory; suppresses osteoclastogenesis in PDL cells | None | T4 | Investigational adjunct for post-extraction healing and palatal mucosal wounds[15][16][17] | Compounded; regulatory pending[10] | "Strongest dental-relevant preclinical signal of the Opal peptides; ophthalmic-surface human safety precedent (mixed efficacy); no dental human trial." |
Reference protocols by clinical scenario
Six protocol cards covering peptide, route, literature-reported dose range, duration, monitoring, contraindications, and regulatory framing. RUO clinician-education default throughout. Click any card to expand; all cards print fully expanded.
I-1 · Post-extraction socket healing in compromised patients
Indication framing (research-grade): Patient with one or more healing-impairment factors (diabetes, smoking history, prior bisphosphonate exposure inside the MRONJ-risk window, immunosuppression, or prior delayed-healing socket) undergoing routine or surgical extraction. Goal is to support soft-tissue closure and early bone fill, not to replace standard socket preservation technique.
| Primary peptide | |
|---|---|
| Peptide | BPC-157 |
| Route | Subcutaneous (peri-incisional or abdominal); oral capsule as lower-evidence alternative |
| Dose range (literature-reported) | 250–500 µg/day SC; oral 250–500 µg/day where SC is declined, with caveat that oral bioavailability data in humans is thin |
| Duration | 3–5 days pre-extraction plus 10–14 days post-extraction; some clinician reports extend to 21 days for high-risk sockets |
| Reconstitution | Lyophilized 5 mg vial reconstituted with 2.5–5 mL bacteriostatic water; refrigerate after reconstitution; use within ~30 days |
| Optional adjunct | |
|---|---|
| Peptide | GHK-Cu, topical |
| Route | Topical rinse or gel at socket margin; or constituent of a collagen plug carrier |
| Dose range | 0.05–0.2% GHK-Cu (dermatology formulation literature); intraoral topical use is extrapolated |
| Duration | Twice daily for 7–14 days post-procedure |
Monitoring: 48-hour and 7-day soft-tissue check standard; flag delayed epithelial closure beyond day 10, persistent pain disproportionate to clinical findings, dry socket. Discontinue and revert to standard of care if any adverse local reaction.
Contraindications / cautions: Active or recent (within 5 years) malignancy is the most-cited theoretical caution for BPC-157 due to angiogenic peptide concerns around tumor vascularization. Pregnancy/lactation: insufficient data, defer. Known hypersensitivity. Bisphosphonate use: peptide adjunct does not eliminate MRONJ risk.
Drug-drug interactions: No clinically documented interactions with amoxicillin, clindamycin, metronidazole, or short-course NSAIDs.
Regulatory framing: RUO clinician-education default. 503A compounding pharmacy pathway available in scope-broad states; BPC-157 SC is commonly compounded.
I-2 · Post-implant osseointegration support
Indication framing: Adjunct to a properly planned implant placement where the operator wants additional soft-tissue and early peri-implant bone support. Not a replacement for primary stability, appropriate implant selection, or graft technique.
| Primary peptide | |
|---|---|
| Peptide | BPC-157 |
| Route | Subcutaneous |
| Dose range | 250–500 µg/day SC; some research-grade reports use twice-daily 250 µg in the first 7 days |
| Duration | 5–7 days pre-placement plus 14–30 days post-placement; longer end reserved for grafted or sinus-lift cases |
| Adjunct peptide | |
|---|---|
| Peptide | TB-500 (Tβ4 fragment or full TB4) |
| Route | Subcutaneous |
| Dose range | 2.0–2.5 mg twice weekly for a loading 4–6 week window in commonly cited research-grade protocols; numbers originate largely from sports-medicine and veterinary literature |
| Duration | Loading phase covering weeks 1–6 post-placement |
Optional topical: GHK-Cu 0.05–0.2% peri-implant sulcus application or rinse, twice daily for 14 days post-placement.
Monitoring: 2-week, 6-week, and 12-week peri-implant soft-tissue and probing-depth check. Flag early implant mobility or radiographic crestal bone loss beyond expected remodeling.
Contraindications: Active/recent malignancy. TB-500 carries similar theoretical angiogenic-tumor caution. Diabetes and smoking remain independent risk factors regardless of peptide adjunct.
Drug-drug interactions: No documented DDI with typical implant-pharmacotherapy stack (amoxicillin or clindamycin prophylaxis, chlorhexidine rinse, short-course NSAIDs). Corticosteroid co-administration may blunt repair signal (mechanistic caution).
Regulatory framing: RUO default. 503A compounded Rx in scope-broad states; TB-500 less commonly compounded than BPC-157, pharmacy availability varies.
I-3 · Periodontal regenerative procedures adjunct
Indication framing: Adjunct to GTR, bone graft, or open-flap debridement in moderate-to-severe periodontitis. Goal: support soft-tissue closure and early regenerative window. Not a replacement for flap design, biomaterial selection, or recall hygiene.
| Primary peptide | |
|---|---|
| Peptide | BPC-157 |
| Route | Subcutaneous |
| Dose range | 250–500 µg/day SC |
| Duration | 3–5 days pre-surgery plus 14–21 days post-surgery |
| Adjunct peptides | |
|---|---|
| GHK-Cu topical | 0.05–0.2%; single intra-operative application plus twice-daily 0.05% oral rinse 7–14 days |
| KPV oral rinse | 200–500 µg, twice daily for 7–14 days; evidence base is GI mucosal anti-inflammatory in animal models, extrapolated to oral mucosa |
Monitoring: 2-week, 6-week, and 3-month re-evaluation of probing depth, BoP, CAL. Standard periodontal monitoring cadence. Flag persistent suppuration, dehiscence, or membrane exposure.
Contraindications: Active untreated systemic periodontitis-associated conditions (uncontrolled diabetes, active smoking) should be addressed independently; peptide adjunct does not substitute for systemic risk-factor control.
Drug-drug interactions: No documented DDI with chlorhexidine, doxycycline, amoxicillin-metronidazole, or short-course NSAIDs.
Regulatory framing: RUO clinician-education default. Sub-gingival placement of compounded peptide is a research-grade practice; document accordingly.
I-4 · Mucogingival surgery soft-tissue support
Indication framing: Adjunct to FGG, CTG, or coronally advanced flap. Goal: graft-site soft-tissue maturation and donor-site comfort.
| Primary peptide | |
|---|---|
| Peptide | BPC-157 |
| Route | Subcutaneous |
| Dose range | 250–500 µg/day SC |
| Duration | 2–3 days pre-procedure plus 10–14 days post-procedure |
| Adjunct peptide | |
|---|---|
| Peptide | GHK-Cu, topical |
| Route | Topical at graft and donor sites |
| Dose range | 0.05–0.2% |
| Duration | Twice daily, 7–14 days |
Evidence note: The dermatology literature for GHK-Cu and skin re-epithelialization is the strongest evidence base for any peptide in this package; mucogingival translation is reasonable but not directly trial-validated in dentistry.
Monitoring: 1-week and 4-week graft site evaluation. Flag graft sloughing, donor-site bleeding beyond day 3, or pain disproportionate to clinical findings.
Contraindications: Active/recent malignancy as above. Copper hypersensitivity is the GHK-Cu-specific consideration; uncommon but documented.
Regulatory framing: RUO default. Topical GHK-Cu in cosmetic formulation strengths is widely available outside a compounded Rx pathway, simplifying regulatory framing for the topical adjunct.
I-5 · Peri-implantitis adjunctive management
Indication framing: Adjunct to mechanical and chemical decontamination in established peri-implantitis. Goal: support soft-tissue resolution and bone-defect stabilization alongside standard surgical or non-surgical management. Not a substitute for decontamination or, where indicated, explantation.
| Primary peptide | |
|---|---|
| Peptide | BPC-157 |
| Route | Subcutaneous |
| Dose range | 250–500 µg/day SC |
| Duration | 14–30 days post-decontamination; longer courses (up to 8 weeks) appear in research-grade reports for advanced defects |
| Adjunct peptides | |
|---|---|
| GHK-Cu topical | 0.05–0.2%; single intra-operative irrigation plus twice-daily rinse 14 days |
| KPV oral rinse | 200–500 µg per dose, twice daily, 14 days. Anti-inflammatory rationale; not validated as standalone peri-implantitis therapy |
Monitoring: Probing depth, suppuration, BoP at 2 weeks, 6 weeks, 3 months. Radiographic re-evaluation at 6 and 12 months. Flag continued probing-depth progression, recurrent suppuration, or radiographic bone-loss progression.
Contraindications: As above. Patients with multiple failed implants on the same arch warrant a full systemic-factor work-up independent of peptide adjunct.
Regulatory framing: RUO default. Peptide adjunct should be framed as supportive, not curative.
I-6 · Oral mucositis (chemo / radiation patients)
Indication framing: Patient receiving head-and-neck radiation or stomatotoxic chemotherapy with grade 1–3 oral mucositis. Adjunct to standard supportive care.
| Primary peptide | |
|---|---|
| Peptide | GHK-Cu, topical |
| Route | Oral rinse |
| Dose range | 0.05–0.2% topical, 5–10 mL swish 30–60 seconds, expectorate |
| Duration | 3–4 times daily during active mucositis window |
Evidence note: Strongest evidence base of any peptide in this list (decades of GHK-Cu wound healing literature in dermatology). Oral mucositis specifically: limited but supportive case-series and small trials.
| Adjunct peptides | |
|---|---|
| KPV oral rinse | 200–500 µg per dose, 2–3 times daily; active mucositis window |
| BPC-157 oral / sublingual | 250–500 µg per dose, 1–2 times daily, topical mucosal contact (not systemic SC in this population). The mucosal topical rationale rests on local epithelial repair without the systemic exposure profile of SC; this distinction is mechanistic, not trial-validated. |
Monitoring: WHO oral mucositis grading at every visit. Surveillance for opportunistic infection. Coordinate with oncology team on any peptide adjunct.
Drug-drug interactions: No documented DDI with typical mucositis supportive stack (lidocaine viscous, nystatin, doxepin rinse, opioid analgesia). Mechanistic caution with concurrent immunotherapy or angiogenesis-targeted oncology drugs; oncology team owns that call.
Regulatory framing: RUO default. This is the scenario where the regulatory and ethical framing is most consequential; document oncology coordination and informed consent specifically.
Practical considerations: chair time, integration, cost
The operational integration questions a practice owner asks before committing to a peptide adjunct workflow.
Case workflow integration
| Phase | Practitioner action | Patient action |
|---|---|---|
| Pre-op consent (1–2 weeks before) | Discuss peptide adjunct rationale; document RUO or 503A framing; obtain informed consent; confirm no active malignancy | Patient acknowledges research-grade framing; confirms medical history; for SC routes, completes injection-technique orientation |
| Pre-op dose start (3–7 days before) | Dispense or prescribe per pathway; provide reconstitution and storage instructions in writing | Patient initiates pre-op dosing window at home |
| Day of procedure | Standard procedural workflow; topical peptide adjunct applied at closure where indicated (adds 2–5 min); document peptide use in op note | Patient continues home dosing schedule per protocol |
| Post-op continuation (10–30 days) | Standard post-op call at 48 hours and standard recall; peptide-specific check at 2 weeks for soft-tissue maturation | Patient continues dosing through protocol window; reports adverse local reaction |
| Follow-up | Standard procedure-specific recall; peptide adjunct does not change cadence | Patient discontinues peptide at end of protocol unless extended |
Chair-time impact
| Adjunct type | Chair-time delta per case |
|---|---|
| Systemic SC peptide (patient self-administers) | 0 min intra-op; ~5–10 min added to consent and dispense at pre-op visit |
| Topical peptide at closure | 2–5 min intra-op |
| Oral rinse adjunct (home use) | 0 min intra-op; ~2 min patient instruction |
| Combination protocol (systemic + topical + rinse) | 5–7 min intra-op plus ~10 min pre-op consent and dispense |
Cost-of-goods bands
Practice acquisition cost ranges for research-grade material through a quality-vetted supplier with batch-level COAs. These are illustrative ranges, not retail or compounded-Rx prices; confirm with the practice's specific supplier.
| Peptide | Typical vial size | Practice acquisition cost per vial |
|---|---|---|
| BPC-157 | 5 mg lyophilized | $25–$65 |
| TB-500 | 2–5 mg lyophilized | $40–$120 |
| GHK-Cu | 50–100 mg lyophilized (systemic); topical formulation varies | $20–$70 systemic; topical varies by carrier |
| KPV | 5–10 mg lyophilized | $30–$80 |
Patient-facing pricing benchmarks
What practices in the field actually charge varies widely; this is reported as the field's range, not a recommendation. Pricing should reflect the practice's overall cash-pay positioning and procedural margin.
| Protocol type | Patient-facing fee range (field-reported) |
|---|---|
| Single peptide adjunct, short course (10–14 days post-op) | $150–$400 per case |
| Combined peptide protocol (systemic + topical) | $300–$800 per case |
| Extended course (peri-implantitis adjunct, 4–8 weeks) | $600–$1,500 per case |
| Mucositis supportive rinse course | $200–$500 per course |
Documentation and informed consent (minimum set)
| Document | Purpose |
|---|---|
| Peptide-adjunct informed consent | RUO framing; research-grade nature; absence of FDA approval for dental indication; known cautions; patient's acknowledgment |
| Pre-op medical history attestation | Patient confirms no active malignancy, no recent malignancy in conservative window, no pregnancy/lactation, no known peptide allergy |
| Op-note documentation | Specific peptide, dose, route, batch and lot, application time, intra-operative application detail |
| Post-op patient instruction sheet | Reconstitution if applicable, storage, dosing schedule, adverse-reaction reporting |
| Pharmacy or supplier record | Batch-level COA on file for every lot administered or dispensed |
When to refer out
| Refer when | Refer to |
|---|---|
| Active or recent (≤5 yr) solid tumor history with proposed systemic peptide adjunct | Oncology team; defer systemic peptide; reconsider topical-only protocol |
| Head-and-neck radiation mucositis where the practice is not part of the oncology supportive-care plan | Patient's oncology team; coordinate rather than initiate independently |
| Pregnancy or lactation | Defer peptide adjunct entirely |
| Patient on angiogenesis-targeted oncology therapy or immunotherapy | Oncology team owns the call |
| MRONJ-risk patient with proposed surgical extraction | Maxillofacial surgery consultation |
| Suspected peptide hypersensitivity reaction | Allergy / immunology; discontinue and document |
| State scope restriction unclear | Practice's regulatory counsel before any Rx pathway; RUO clinician-education framing safer until clarified |
State scope reminder
| Scope-broad (working examples) | Scope-restrictive (working examples) |
|---|---|
| Texas, Florida, Arizona | California, New York, Massachusetts |
Compounded peptide Rx via 503A partner is operationally more accessible in the scope-broad column; the scope-restrictive column requires explicit confirmation of the state dental board's position before any Rx pathway. The RUO clinician-education framing is the safer default in any state until confirmed. This is a regulatory landscape that changes; this reflects the working examples used in this package, not a substitute for current-day state-by-state legal review.
Webinar outline (host's guide)
A 60-minute clinician-education webinar for an Opal practitioner advisor to deliver to dental clinicians. Time / slide budgets, speaker notes, visual recommendations, and prepared objection handling per section.
| Host | Practitioner advisor (TBD by Jay) |
| Audience | General dentists, periodontists, OMS, implant specialists |
| Length | 60 min (45 min content + 15 min Q&A) |
| Format | Live, recorded for asynchronous access |
| Goals | Establish credibility with skeptical clinician audience · translate research-tier biology into chair-side relevance · open discovery conversations with attendees who have specific cases |
Open with a case, not a brand
A single case from the literature, not a brand testimonial. Recommended frame: a published or case-series example of post-extraction healing where a peptide adjunct shortened the soft-tissue recovery window, or a periodontal regeneration case where the adjunctive arm showed clearer attachment gain. Name the source by tier (peer-reviewed human trial, animal model, case report) so the audience hears calibration in the first 60 seconds. The line that carries the cold open: "I am not here to sell you a peptide. I am here to walk you through what the dental literature actually says, and to tell you where it stops."
Visuals: one clinical photo from the cited case if rights allow, otherwise a clean histology or radiograph. No Opal branding on the cold-open slides.
Why dentistry, why now
Three beats. First, the peptide market is crowded everywhere except dentistry. Second, the dental biology is more rigorous than the mass-market peptide story has been. Third, what this means for an early-adopter practice: an opportunity to be the credible voice on a topic the rest of the field has not engaged with yet, built on the strongest dental peptide indications first.
Anticipated objection: "If the biology is so good, why has nobody done this?" Answer: peptides have been a consumer story; dentistry needs a clinician-supplied pathway, which is what Opal is building.
The dental wound healing primer
A clean refresher framed for the room. Soft tissue, hard tissue, and ligament/attachment healing each follow distinct kinetics. The peptide story sits inside the proliferation and early remodeling phases, not initial hemostasis or late maturation.
Visuals: a four-phase wound-healing timeline annotated with where each peptide exerts its proposed effects; healthy vs compromised healing trajectories; a periodontal attachment apparatus schematic.
Peptide by peptide
Four molecules, one-slide summary of identity/mechanism and one slide of dental indication/evidence tier each. State the tier out loud. The room will trust the talk more if you call TB-500 the strongest dental-relevant preclinical signal (rather than BPC-157, which is the popular default). GHK-Cu's dental-specific evidence is mechanistic only; do not import dermatology copy.
Anticipated objection: "Why these four?" Answer: cleanest combination of mechanistic plausibility, available research-grade supply, and any meaningful dental or adjacent literature. Others (CJC, ipamorelin, AOD-9604) have weaker dental relevance or stronger off-label baggage.
Six clinical scenarios
Walk through the six scenarios from Section B at 2.5 min each, in four beats per scenario: clinical setup, peptide role, evidence tier, candidate patient. Standardized two-slide template per scenario. This is where the room mentally maps their own patients.
Anticipated objections: "How does this interact with my regen membrane and graft?" Honest answer: no head-to-head trials; protocols are adjunctive. "Peri-implantitis surgical decontamination is the gold standard." Acknowledged; peptide role is post-decontamination soft-tissue and inflammatory environment, not replacement.
The honest limits — credibility section
Three honest statements: most evidence is preclinical or early-human; regulatory pathway is clinician-directed research-grade through 503A, not FDA-cleared; certain patients are not candidates (active malignancy, pregnancy, immunocompromised states, unstable systemic disease).
If you ever hear an Opal advisor describe a peptide as a cure, an indication, or a standard of care, that is a sign you should walk away from that conversation.
This section is for the periodontists in the room. If they nod here, they will refer cases.
Practical integration
Four practical questions in order: chair-time (minimal), regulatory framing (RUO and 503A), supply (clinician-pharmacy relationship, Opal facilitates), case selection (Section I protocol reference and the Opal advisor team for case-specific consultation).
Anticipated objection: "Liability exposure?" Honest answer: standard scope-of-practice and informed consent rules apply; Section R walks through the compliance frame; not legal advice on the webinar.
Prepared FAQ — rehearse before live session
- Strongest single piece of human dental evidence on BPC-157? Direct to Section F; state sample size and tier honestly.
- Can I prescribe directly or need 503A? 503A is the appropriate pathway. Opal does not ship to patients.
- What does it cost the patient? Defer to advisor for current pharmacy pricing; order of magnitude for typical 4–6 week post-surgical protocol is low-to-mid hundreds, not thousands.
- State board position on compounded peptides? State scope-of-practice varies; compliance section summarizes the frame; specific state positions require regulatory consultation.
- Evidence tier for a specific scenario? Protocol reference and evidence sections are organized exactly this way.
- Adverse event risk? Reported rates in existing literature are low; patient categories listed in Section 5 are not candidates; consent conversation should be explicit.
- How is Opal different from consumer peptide brands? Clinician-supplied only, RUO-framed, indication-led case work.
Soft close, three options
Book a discovery call. Request a case-specific consultation. Join the dental practitioner pilot cohort. The line: "We are not asking anyone in this room to change their standard of care. We are asking for the dental cases where the standard of care leaves something on the table, and we want to be the clinician-supplied option you trust when those cases come up."
Visuals: one slide with three clear next-step options and contact routing. No hard sell, no countdown timer, no pricing.
Compliance-aware close + RUO statement
The standard close that appears at the end of every Opal clinician communication.
Research-use only framing
The peptides referenced in this package are supplied for research-use-only and clinician-directed use through licensed 503A compounding pharmacy pathways. None of the peptides referenced in this package are FDA-approved for the dental indications described. References to clinical scenarios are educational and reflect the published research literature, not standard-of-care recommendations.
Scope of practice and state variation
Dental scope of practice and the regulatory treatment of compounded peptide therapeutics vary by state. The clinician is responsible for confirming local board, state pharmacy, and applicable regulatory positions before incorporating any adjunctive protocol referenced in this package. Opal does not substitute for state-specific regulatory guidance.
503A compounding pharmacy pathway
Supply for clinician-directed peptide protocols described here is through 503A compounding pharmacies, on a patient-specific prescription basis, supplied to or through the licensed clinician. This pathway is distinct from FDA-approved pharmaceutical supply and from direct-to-consumer wellness peptide products. The Opal advisor team can facilitate introductions to appropriately licensed 503A partners.
Liability and informed consent
Adjunctive use of research-grade peptides in a clinical setting requires explicit informed consent, including disclosure of non-FDA-approved status, the tier of evidence for the specific indication, the alternatives available, and the expected and possible adverse outcomes. The clinician is responsible for documenting consent and for the case-by-case judgment of fit. Sections F through J summarize the evidence frame referenced in consent conversations; they do not constitute consent language.
Source citation framework
Citations in this package are graded by evidence tier. Where the evidence is preclinical-leaning, the package says so. Where the evidence is established in adjacent fields (e.g., GHK-Cu in dermatologic wound healing) and being extended into dental contexts, the package distinguishes between the established source field and the dental application.
Honest gap statement
Peptide marketing in adjacent categories has consistently outrun the data. The dental evidence base is, in several specific indications, stronger than the marketing claims in performance and wellness peptide categories. It is not, however, stronger than the marketing claims that some peptide vendors have made for dental use. Opal's position is that the dental peptide story should be told at the tier the evidence actually supports, no further. Where this package describes an indication as preclinical-leaning, the honest read is that the chair-side decision is still a clinician's judgment call, supported by mechanism and early signal, not by a finished body of human trial work.
Sales follow-up sequence
A 5-touch 30-day sequence calibrated to clinician-respect tone. For the Opal rep's use post-package handoff.
T+0 — Initial delivery
Subject: "Opal dental package, with a one-paragraph reason it landed in your inbox."
One-paragraph reason-to-engage customized to the recipient's practice. Template: "Dr. [Name], the dental package attached was assembled by a working dental advisor, a research lead, and a clinical pharmacologist, and it is the first piece of clinician-facing dental work Opal has put together. I sent it to you because [specific reason tied to recipient practice: implant volume, perio focus, mucogingival case mix, peri-implantitis caseload]. The exec summary on page one is the fastest read. If anything in Section B maps to a current case, the protocol reference in Section I is where I would start." Sign-off names the Opal advisor and offers a discovery call link.
T+3 — Practitioner case content
Short follow-up tied to the section most likely to be relevant. Example for an implant-heavy practice: "I wanted to flag Section B2 on early osseointegration support. The evidence tier is preclinical-leaning, but the candidate-patient framework in the protocol reference is the part most of the implant-focused dentists I have spoken to have found useful. No reply needed, just flagging."
T+7 — Webinar invite or recording
If next live webinar is within 30–90 days: "We are running a 60-minute clinician webinar on [date]. The outline is in Section Q of the package. If you want to attend live or send a colleague, here is the link."
If a recording is already available: "The webinar recording is here. Section 4 (the six clinical scenarios) starts at the 18-minute mark." No follow-up question, no soft pressure.
T+14 — Soft check-in offering one specific case-review call
"Dr. [Name], it has been about two weeks since I sent the dental package. The offer that has been most useful for the dentists I work with is a 20-minute case review with one of our clinical advisors, on a specific patient case you are considering. No prep needed on your end beyond the case context. If a slot in the next week or two would be useful, here is the link." Calendly link, no other CTA.
T+28 — Final follow-up with two clear next steps
"Dr. [Name], closing the loop on the dental package. Two clear options if any of it landed:
- A 20-minute clinical advisor case review, scheduling link here.
- Join the dental practitioner pilot cohort: early access, the option to contribute to the case-series writeup we are building, and direct line to the Opal clinical team. Details one click away.
If neither is a fit right now, no follow-up from me. The package is yours to keep and reference. If a case comes up in six months, the discovery call link still works."
The 30-day window closes here. No further outreach unless the practitioner re-engages or a new package iteration ships.
References
Master reference list cited throughout the package. Every PMID and DOI was verified against PubMed or publisher of record during preparation. Numbered for inline superscript citation throughout.
- Keremi B, Lohinai Z, Komora P, et al. Antiinflammatory effect of BPC 157 on experimental periodontitis in rats. J Physiol Pharmacol. 2009; 60 Suppl 7:115-22. PMID: 20388954. Single rat ligature-induced periodontitis study showing reduced gingival inflammation and alveolar bone resorption with systemic BPC-157. Primary dental-relevant in-vivo evidence for BPC-157.
- Hsieh MJ, Liu HT, Wang CN, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020; 10:17078. DOI: 10.1038/s41598-020-74022-y.
- Seiwerth S, Milavic M, Vukojevic J, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021; 12:627533. PMID: 34267654.
- Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006; 24(5):982-9. PMID: 16583442.
- Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. 2016; 14(8):857-865. PMID: 27138887.
- Gjurasin M, Miklic P, Zupancic B, et al. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury. Regul Pept. 2010; 160(1-3):33-41. PMID: 19903499.
- Sikiric P, Seiwerth S, Rucman R, et al. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Curr Med Chem. 2012; 19(1):126-32. PMID: 22300085.
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021; 27(4):8-13. PMID: 34324435. Retrospective chart review, n=16; methodologically weak.
- Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025; 31(5):20-24. PMID: 40131143. N=2 IV infusion pilot; underpowered for safety conclusions.
- US FDA. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks; 503A Bulks List nomination process. Center for Drug Evaluation and Research. Accessed May 2026. FDA link. BPC-157, KPV, TB-500, and MOTs-C scheduled for PCAC review on July 23, 2026.
- World Anti-Doping Agency. WADA Prohibited List, Section S0 (Non-Approved Substances). Updated annually. BPC-157 is prohibited at all times for athletes under WADA jurisdiction.
- Maquart FX, Pickart L, Laurent M, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988; 238(2):343-6. PMID: 3169264.
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015; 2015:648108. PMID: 26236730.
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018; 19(7):1987. PMID: 29986520.
- Matsuo K, Akasaki Y, Adachi K, et al. Promoting effects of thymosin β4 on granulation tissue and new bone formation after tooth extraction in rats. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012; 114(1):17-26. PMID: 22732845. Primary dental-specific animal evidence for TB-500.
- Zhu T, Park HC, Son KM, et al. Effects of thymosin β4 on wound healing of rat palatal mucosa. Int J Mol Med. 2014; 34(3):816-821. Second dental-relevant animal study for TB-500.
- Lee SI, Yi JK, Bae WJ, et al. Thymosin Beta-4 Suppresses Osteoclastic Differentiation and Inflammatory Responses in Human Periodontal Ligament Cells. PLOS ONE. 2016; 11(1):e0146708. In-vitro human PDL cell study.
- Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999; 113(3):364-8. PMID: 10469335.
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther. 2012; 12(1):37-51. PMID: 22074294.
- Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015; 34(5):491-496. PMID: 25826322.
- Sosne G, Kleinman HK, Springs C, et al. 0.1% RGN-259 (Thymosin β4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. Int J Mol Sci. 2023; 24(1):554. PMID: 36613994. Primary endpoint p=0.0656 (narrowly missed); secondary efficacy signals.
- Sosne G, Chan CC, Thai K, et al. Thymosin beta 4 promotes corneal wound healing and modulates inflammatory mediators in vivo. Exp Eye Res. 2001; 72(5):605-608. PMID: 11311052.
- Yang J, Cheng F, Yao H, et al. In situ mucoadhesive hydrogel capturing tripeptide KPV: the anti-inflammatory, antibacterial and repairing effect on chemotherapy-induced oral mucositis. Biomater Sci. 2022; 10(1):227-242. DOI: 10.1039/d1bm01466h. Primary dental-relevant animal evidence for KPV.
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008; 134(1):166-78. PMID: 18061177.
- Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14(3):324-31. PMID: 18092346.
- Esposito M, Grusovin MG, Papanikolaou N, et al. Enamel matrix derivative (Emdogain) for periodontal tissue regeneration in intrabony defects. A Cochrane systematic review. Eur J Oral Implantol. 2009; 2(4):247-66. PMID: 20467602.
- Tavelli L, Chen CJ, Barootchi S, Kim DM. Efficacy of biologics for the treatment of periodontal infrabony defects: An AAP best evidence systematic review and network meta-analysis. J Periodontol. 2022; 93(12):1803-1826. PMID: 36279121.
- Avila-Ortiz G, Ambruster J, Barootchi S, et al. AAP best evidence consensus statement on the use of biologics in clinical practice. J Periodontol. 2022; 93(12):1763-1770. PMID: 36279407.
- Nevins M, Giannobile WV, McGuire MK, et al. Platelet-Derived Growth Factor Stimulates Bone Fill and Rate of Attachment Level Gain. J Periodontol. 2005; 76(12):2205-15. Pivotal RCT for GEM 21S (n=180).
- Kao RT, Nares S, Reynolds MA. Periodontal regeneration - intrabony defects: a systematic review from the AAP Regeneration Workshop. J Periodontol. 2015; 86(2 Suppl):S77-104. PMID: 25216204.
- Boyne PJ, Marx RE, Nevins M, et al. A feasibility study evaluating rhBMP-2/absorbable collagen sponge for maxillary sinus floor augmentation. Int J Periodontics Restorative Dent. 1997; 17(1):11-25. PMID: 10332250.
- Boyne PJ, Lilly LC, Marx RE, et al. De novo bone induction by recombinant human bone morphogenetic protein-2 (rhBMP-2) in maxillary sinus floor augmentation. J Oral Maxillofac Surg. 2005; 63(12):1693-707. PMID: 16297689.
Methodology: every PMID/DOI above was verified against PubMed or publisher of record during preparation by the scientific-researcher agent. No citations were fabricated. Marketing-site material (peptides.org, vendor blogs) was excluded. Every claim in this package resolves to a numbered reference above.